

COVID 19 Pseudoviral Particles, JN.1 Variant Coronavirus Pseudovirus | COVID-19 pseudovirus

SARS-CoV-2 Pseudoviral Particles, JN.1 Variant

CATALOG #

AAA62259


PRODUCT SYNONYMS

COVID 19 Pseudoviral Particles; JN.1 Variant Coronavirus; SARS-CoV-2 Pseudoviral Particles; JN.1 Variant; 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; COVID-19 pseudovirus

PRODUCT SPECIFICATIONS


Key Features	- High Signal-to-Noise Ratio: Enables sensitive detection - HTS-Compatible: Validated for 96-, 384-, and 1536-well formats - Convenient Format: Ready-to-use for luciferase-based entry assays
Product Contents	- Volume: 1 mL or 5 mL (suitable for multi-well plates) - Titer: $> 1.0 \times 10^7$ particles/mL
Dry Ice Note	The product may be shipped with dry ice, and an additional fee may be added to your shipping cost.
Preparation and Storage	Store immediately at -80 degree C upon receipt - Thaw rapidly at room temperature (<30 min, no shaking); use immediately - Do not aliquot or refreeze - Shelf Life: 6 months from date of receipt when stored at -80 degree C

IMAGES



Application Data

Figure 2. Assay: HEK293-ACE2 cells infected with JN.1 pseudoviral particles. Readout: Relative Luminescence Units (RLU). (-): Negative control: MLV without spike protein (Catalog # JN.1: JN.1 variant pseudovirus)



Application Data

Figure 1. Illustration of the replication-deficient MLV particle pseudotyped with SARS-CoV-2 Spike protein

ADDITIONAL INFORMATION

Related Product Information for COVID-19 pseudovirus

SARS-CoV-2 utilizes human ACE2 as its entry receptor and requires proteolytic activation by host proteases. The viral spike (S) protein mediates cell entry by binding to ACE2 via its receptor-binding domain (RBD), followed by activation through proteolysis.

JN.1 Pseudoviral Particles are replication-deficient murine leukemia virus (MLV) particles pseudotyped with the SARS-CoV-2 spike protein from the JN.1 variant. These particles encode firefly luciferase as a reporter, enabling quantification of viral entry via luminescence. This system isolates the entry step from the rest of the viral life cycle, making it ideal for treated assays.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.